Literature DB >> 28474686

PCOS: Animal models for PCOS - not the real thing.

Ricardo Azziz1.   

Abstract

Mesh：

Year:  2017        PMID： 28474686     DOI： 10.1038/nrendo.2017.57

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  9 in total

1.  Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.

Authors:  C A Eagleson; M B Gingrich; C L Pastor; T K Arora; C M Burt; W S Evans; J C Marshall
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

2.  Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome.

Authors:  Aimee S L Caldwell; Melissa C Edwards; Reena Desai; Mark Jimenez; Robert B Gilchrist; David J Handelsman; Kirsty A Walters
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-20       Impact factor: 11.205

3.  Hormonal effects of flutamide in young women with polycystic ovary syndrome.

Authors:  V De Leo; D Lanzetta; D D'Antona; A la Marca; G Morgante
Journal:  J Clin Endocrinol Metab       Date:  1998-01       Impact factor: 5.958

4.  Ovulatory effects of flutamide in the polycystic ovary syndrome.

Authors:  Roberto Paradisi; Raffaella Fabbri; Cesare Battaglia; Stefano Venturoli
Journal:  Gynecol Endocrinol       Date:  2013-01-18       Impact factor: 2.260

5.  Endocrine and clinical effects of spironolactone in female hyperandrogenism.

Authors:  R Siegberg; P Ylöstalo; T Laatikainen; R Pelkonen; U H Stenman
Journal:  Arch Gynecol       Date:  1987

6.  Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation.

Authors:  Lourdes Ibáñez; Carme Valls; Angela Ferrer; Ken Ong; David B Dunger; Francis De Zegher
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

7.  Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.

Authors:  A S L Caldwell; L J Middleton; M Jimenez; R Desai; A C McMahon; C M Allan; D J Handelsman; K A Walters
Journal:  Endocrinology       Date:  2014-05-30       Impact factor: 4.736

8.  Spironolactone therapy for hyperandrogenic anovulatory women--clinical and endocrinological study.

Authors:  T Masahashi; M C Wu; M Ohsawa; M Asai; Y Ichikawa; K Hanai; H Kikkawa; S Mizutani; O Narita; Y Tomoda
Journal:  Nihon Sanka Fujinka Gakkai Zasshi       Date:  1986-01

Review 9.  Polycystic ovary syndrome.

Authors:  Ricardo Azziz; Enrico Carmina; ZiJiang Chen; Andrea Dunaif; Joop S E Laven; Richard S Legro; Daria Lizneva; Barbara Natterson-Horowtiz; Helena J Teede; Bulent O Yildiz
Journal:  Nat Rev Dis Primers       Date:  2016-08-11       Impact factor: 52.329
  9 in total
  8 in total

Review 1.  Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome.

Authors:  Elisabet Stener-Victorin; Vasantha Padmanabhan; Kirsty A Walters; Rebecca E Campbell; Anna Benrick; Paolo Giacobini; Daniel A Dumesic; David H Abbott
Journal:  Endocr Rev       Date:  2020-07-01       Impact factor: 19.871

2.  Pituitary P62 deficiency leads to female infertility by impairing luteinizing hormone production.

Authors:  Xing Li; Ling Zhou; Guiliang Peng; Mingyu Liao; Linlin Zhang; Hua Hu; Ling Long; Xuefeng Tang; Hua Qu; Jiaqing Shao; Hongting Zheng; Min Long
Journal:  Exp Mol Med       Date:  2021-08-27       Impact factor: 8.718

Review 3.  Polycystic Ovary Syndrome: An Evolutionary Adaptation to Lifestyle and the Environment.

Authors:  Jim Parker; Claire O'Brien; Jason Hawrelak; Felice L Gersh
Journal:  Int J Environ Res Public Health       Date:  2022-01-25       Impact factor: 3.390

4.  The PNA mouse may be the best animal model of polycystic ovary syndrome.

Authors:  Jingyi Ren; Guangqing Tan; Xinyi Ren; Weiyu Lu; Qiling Peng; Jing Tang; Yingxiong Wang; Biao Xie; Meijiao Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-08       Impact factor: 6.055

5.  An Ovarian Steroid Metabolomic Pathway Analysis in Basal and Polycystic Ovary Syndrome (PCOS)-like Gonadotropin Conditions Reveals a Hyperandrogenic Phenotype Measured by Mass Spectrometry.

Authors:  Emma S Gargus; Yeunook Bae; Jiexi Chen; Kristine J Moss; Asia N Ingram; Jiyang Zhang; Nathan T Montgomery; Christina E Boots; William E Funk; Teresa K Woodruff
Journal:  Biomedicines       Date:  2022-07-08

6.  Abnormal GnRH Pulsatility in Polycystic Ovary Syndrome: Recent Insights.

Authors:  Christopher R McCartney; Rebecca E Campbell
Journal:  Curr Opin Endocr Metab Res       Date:  2020-04-23

7.  High Doses of D-Chiro-Inositol Alone Induce a PCO-Like Syndrome and Other Alterations in Mouse Ovaries.

Authors:  Arturo Bevilacqua; Jessica Dragotto; Micaela Lucarelli; Giovanna Di Emidio; Giovanni Monastra; Carla Tatone
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

8.  In rats with estradiol valerate-induced polycystic ovary syndrome, the acute blockade of ovarian β-adrenoreceptors improve ovulation.

Authors:  Berenice Venegas; Lizzbeth Yureli De León Gordillo; Gabriela Rosas; Julieta A Espinoza; Carolina Morán; Roberto Domínguez; Leticia Morales-Ledesma
Journal:  Reprod Biol Endocrinol       Date:  2019-11-19       Impact factor: 5.211
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.